Mississauga, ON -- (SBWIRE) -- 01/15/2014 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Elite Pharmaceuticals Initiates More Bioequivalency Studies.”
Companies mentioned in this article include Elite Pharmaceuticals, Inc. (OTCBB:ELTP).
Article Excerpt:
After starting a serious bull run in 2012, biotech stocks had an incredible year in 2013 and are starting 2014 at full throttle as well. High-dollar acquisitions over the last couple years have raised the bar for the value of drugs in development, especially those targeting areas of great unmet medical need. The U.S. Food and Drug Administration enacting new policy, namely the breakthrough therapy designation, to expedite development of new drugs has further supported loftier valuations as companies can potentially shave tens of millions of development expenditures and reach commercialization more quickly.
There are countless biotechs that have seen enormous rises in valuations recently, including Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharma aiming to utilize the FDA 505(b)(2) pathway to rapidly bring its drugs to market. In short, a 505(b)(2) designation allows for accelerated development based upon the active ingredient of a new drug candidate being that of an already approved drug.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/420/elite-pharmaceuticals-initiates-more-bioequivalency-studies.htm
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.